BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 17694307)

  • 21. Imaging Early-Stage Metastases Using an
    Mason CA; Carter LM; Mandleywala K; de Souza Franca PD; Meyer JP; Mamun T; Backer JM; Backer MV; Reiner T; Lewis JS
    Mol Imaging Biol; 2021 Jun; 23(3):340-349. PubMed ID: 33156495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
    Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
    J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
    Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
    Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
    Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.
    Velikyan I; Sundberg AL; Lindhe O; Höglund AU; Eriksson O; Werner E; Carlsson J; Bergström M; Långström B; Tolmachev V
    J Nucl Med; 2005 Nov; 46(11):1881-8. PubMed ID: 16269603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.
    Marquez BV; Ikotun OF; Parry JJ; Rogers BE; Meares CF; Lapi SE
    J Nucl Med; 2014 Jun; 55(6):1029-34. PubMed ID: 24732153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
    Levashova Z; Backer M; Hamby CV; Pizzonia J; Backer JM; Blankenberg FG
    J Nucl Med; 2010 Jun; 51(6):959-66. PubMed ID: 20484434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
    Cai H; Li Z; Huang CW; Shahinian AH; Wang H; Park R; Conti PS
    Bioconjug Chem; 2010 Aug; 21(8):1417-24. PubMed ID: 20666401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
    Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
    J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
    Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
    Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET imaging of acute and chronic inflammation in living mice.
    Cao Q; Cai W; Li ZB; Chen K; He L; Li HC; Hui M; Chen X
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1832-42. PubMed ID: 17541586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
    Liu S; Li D; Park R; Liu R; Xia Z; Guo J; Krasnoperov V; Gill PS; Li Z; Shan H; Conti PS
    J Nucl Med; 2013 Jul; 54(7):1094-100. PubMed ID: 23667241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Preclinical and Clinical Evaluation of
    Li F; Zhang Z; Cai J; Chen X; Zhou Y; Ma X; Dong Q; Li F; Xi L
    Clin Cancer Res; 2020 Mar; 26(6):1318-1326. PubMed ID: 31843751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
    Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
    J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation,
    Barta P; Kamaraj R; Kucharova M; Novy Z; Petrik M; Bendova K; Hajduch M; Pavek P; Trejtnar F
    Bioconjug Chem; 2022 Oct; 33(10):1825-1836. PubMed ID: 36197842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment.
    Shi S; Hong H; Orbay H; Graves SA; Yang Y; Ohman JD; Liu B; Nickles RJ; Wong HC; Cai W
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1295-303. PubMed ID: 25801992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor.
    Blankenberg FG; Mandl S; Cao YA; O'Connell-Rodwell C; Contag C; Mari C; Gaynutdinov TI; Vanderheyden JL; Backer MV; Backer JM
    J Nucl Med; 2004 Aug; 45(8):1373-80. PubMed ID: 15299064
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.